TherapeuticsMD, Inc. (NASDAQ: TXMD) Stock Competitors & Peer Comparison
See TXMD's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for TXMD and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| TXMD | $2.09 | +1.95% | 24.2M | 106.47 | $0.02 | N/A |
| TAK | $18.90 | +0.21% | 60.2B | 13.59 | $1.39 | +3.34% |
| TEVA | $38.88 | -0.79% | 45.3B | 13.27 | $2.93 | N/A |
| HLN | $9.17 | -0.97% | 40.4B | 18.78 | $0.49 | +2.16% |
| ZTS | $71.43 | +0.53% | 29.9B | 10.85 | $6.58 | +2.93% |
| VTRS | $18.27 | +2.47% | 21.3B | 7.25 | $2.52 | +2.62% |
| ITCI | $131.87 | +0.00% | 14B | -180.64 | -$0.73 | N/A |
| CTLT | $63.48 | +0.00% | 11.5B | -27.84 | -$2.28 | N/A |
| ELAN | $22.45 | +0.63% | 11.2B | 21.17 | $1.06 | N/A |
| RDY | $12.51 | +2.12% | 10.4B | 20.52 | $0.61 | +0.66% |
Stock Comparison
Takeda Pharmaceutical Company Limited (NYSE: TAK)
TXMD vs TAK Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 24.2M. In comparison, TAK has a market cap of 60.2B. Regarding current trading prices, TXMD is priced at $2.09 on the NASDAQ, while TAK trades at $18.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 106.47, whereas TAK's P/E ratio is 13.59. In terms of profitability, TXMD's ROE is -0.01%, compared to TAK's ROE of +0.02%. Regarding short-term risk, TXMD is more volatile compared to TAK. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check TAK's competition here
Teva Pharmaceutical Industries Limited (NYSE: TEVA)
TXMD vs TEVA Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 24.2M. In comparison, TEVA has a market cap of 45.3B. Regarding current trading prices, TXMD is priced at $2.09 on the NASDAQ, while TEVA trades at $38.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 106.47, whereas TEVA's P/E ratio is 13.27. In terms of profitability, TXMD's ROE is -0.01%, compared to TEVA's ROE of +0.09%. Regarding short-term risk, TXMD is more volatile compared to TEVA. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check TEVA's competition here
Haleon plc (NYSE: HLN)
TXMD vs HLN Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 24.2M. In comparison, HLN has a market cap of 40.4B. Regarding current trading prices, TXMD is priced at $2.09 on the NASDAQ, while HLN trades at $9.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 106.47, whereas HLN's P/E ratio is 18.78. In terms of profitability, TXMD's ROE is -0.01%, compared to HLN's ROE of +0.17%. Regarding short-term risk, TXMD is more volatile compared to HLN. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check HLN's competition here
Zoetis Inc. (NYSE: ZTS)
TXMD vs ZTS Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 24.2M. In comparison, ZTS has a market cap of 29.9B. Regarding current trading prices, TXMD is priced at $2.09 on the NASDAQ, while ZTS trades at $71.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 106.47, whereas ZTS's P/E ratio is 10.85. In terms of profitability, TXMD's ROE is -0.01%, compared to ZTS's ROE of +0.69%. Regarding short-term risk, TXMD is more volatile compared to ZTS. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check ZTS's competition here
Viatris Inc. (NASDAQ: VTRS)
TXMD vs VTRS Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 24.2M. In comparison, VTRS has a market cap of 21.3B. Regarding current trading prices, TXMD is priced at $2.09 on the NASDAQ, while VTRS trades at $18.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 106.47, whereas VTRS's P/E ratio is 7.25. In terms of profitability, TXMD's ROE is -0.01%, compared to VTRS's ROE of -0.03%. Regarding short-term risk, TXMD is less volatile compared to VTRS. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check VTRS's competition here
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI)
TXMD vs ITCI Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 24.2M. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, TXMD is priced at $2.09 on the NASDAQ, while ITCI trades at $131.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 106.47, whereas ITCI's P/E ratio is -180.64. In terms of profitability, TXMD's ROE is -0.01%, compared to ITCI's ROE of -0.09%. Regarding short-term risk, TXMD is more volatile compared to ITCI. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check ITCI's competition here
Catalent, Inc. (NYSE: CTLT)
TXMD vs CTLT Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 24.2M. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, TXMD is priced at $2.09 on the NASDAQ, while CTLT trades at $63.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 106.47, whereas CTLT's P/E ratio is -27.84. In terms of profitability, TXMD's ROE is -0.01%, compared to CTLT's ROE of -0.25%. Regarding short-term risk, TXMD is more volatile compared to CTLT. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check CTLT's competition here
Elanco Animal Health Incorporated (NYSE: ELAN)
TXMD vs ELAN Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 24.2M. In comparison, ELAN has a market cap of 11.2B. Regarding current trading prices, TXMD is priced at $2.09 on the NASDAQ, while ELAN trades at $22.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 106.47, whereas ELAN's P/E ratio is 21.17. In terms of profitability, TXMD's ROE is -0.01%, compared to ELAN's ROE of -0.03%. Regarding short-term risk, TXMD is less volatile compared to ELAN. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check ELAN's competition here
Dr. Reddy's Laboratories Limited (NYSE: RDY)
TXMD vs RDY Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 24.2M. In comparison, RDY has a market cap of 10.4B. Regarding current trading prices, TXMD is priced at $2.09 on the NASDAQ, while RDY trades at $12.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 106.47, whereas RDY's P/E ratio is 20.52. In terms of profitability, TXMD's ROE is -0.01%, compared to RDY's ROE of +0.09%. Regarding short-term risk, TXMD is more volatile compared to RDY. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check RDY's competition here
Alkermes plc (NASDAQ: ALKS)
TXMD vs ALKS Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 24.2M. In comparison, ALKS has a market cap of 6.7B. Regarding current trading prices, TXMD is priced at $2.09 on the NASDAQ, while ALKS trades at $40.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 106.47, whereas ALKS's P/E ratio is 42.26. In terms of profitability, TXMD's ROE is -0.01%, compared to ALKS's ROE of +0.04%. Regarding short-term risk, TXMD is more volatile compared to ALKS. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check ALKS's competition here
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX)
TXMD vs AMRX Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 24.2M. In comparison, AMRX has a market cap of 6.5B. Regarding current trading prices, TXMD is priced at $2.09 on the NASDAQ, while AMRX trades at $20.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 106.47, whereas AMRX's P/E ratio is 22.78. In terms of profitability, TXMD's ROE is -0.01%, compared to AMRX's ROE of -3.27%. Regarding short-term risk, TXMD is less volatile compared to AMRX. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check AMRX's competition here
Lantheus Holdings, Inc. (NASDAQ: LNTH)
TXMD vs LNTH Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 24.2M. In comparison, LNTH has a market cap of 6.5B. Regarding current trading prices, TXMD is priced at $2.09 on the NASDAQ, while LNTH trades at $99.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 106.47, whereas LNTH's P/E ratio is 16.76. In terms of profitability, TXMD's ROE is -0.01%, compared to LNTH's ROE of +0.23%. Regarding short-term risk, TXMD is more volatile compared to LNTH. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check LNTH's competition here
Indivior Pharmaceuticals Inc (NASDAQ: INDV)
TXMD vs INDV Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 24.2M. In comparison, INDV has a market cap of 4.6B. Regarding current trading prices, TXMD is priced at $2.09 on the NASDAQ, while INDV trades at $36.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 106.47, whereas INDV's P/E ratio is 10.10. In terms of profitability, TXMD's ROE is -0.01%, compared to INDV's ROE of -2.16%. Regarding short-term risk, TXMD is less volatile compared to INDV. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check INDV's competition here
Alvotech (NASDAQ: ALVOW)
TXMD vs ALVOW Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 24.2M. In comparison, ALVOW has a market cap of 3.5B. Regarding current trading prices, TXMD is priced at $2.09 on the NASDAQ, while ALVOW trades at $0.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 106.47, whereas ALVOW's P/E ratio is 55.38. In terms of profitability, TXMD's ROE is -0.01%, compared to ALVOW's ROE of +0.77%. Regarding short-term risk, TXMD is more volatile compared to ALVOW. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check ALVOW's competition here
Regencell Bioscience Holdings Limited (NASDAQ: RGC)
TXMD vs RGC Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 24.2M. In comparison, RGC has a market cap of 3.1B. Regarding current trading prices, TXMD is priced at $2.09 on the NASDAQ, while RGC trades at $6.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 106.47, whereas RGC's P/E ratio is -436.62. In terms of profitability, TXMD's ROE is -0.01%, compared to RGC's ROE of -2.32%. Regarding short-term risk, TXMD is less volatile compared to RGC. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check RGC's competition here
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN)
TXMD vs SUPN Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 24.2M. In comparison, SUPN has a market cap of 2.6B. Regarding current trading prices, TXMD is priced at $2.09 on the NASDAQ, while SUPN trades at $44.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 106.47, whereas SUPN's P/E ratio is 14.58. In terms of profitability, TXMD's ROE is -0.01%, compared to SUPN's ROE of -0.10%. Regarding short-term risk, TXMD is less volatile compared to SUPN. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check SUPN's competition here
HUTCHMED (China) Limited (NASDAQ: HCM)
TXMD vs HCM Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 24.2M. In comparison, HCM has a market cap of 2.5B. Regarding current trading prices, TXMD is priced at $2.09 on the NASDAQ, while HCM trades at $14.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 106.47, whereas HCM's P/E ratio is 5.30. In terms of profitability, TXMD's ROE is -0.01%, compared to HCM's ROE of +0.01%. Regarding short-term risk, TXMD is more volatile compared to HCM. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check HCM's competition here
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH)
TXMD vs DCPH Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 24.2M. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, TXMD is priced at $2.09 on the NASDAQ, while DCPH trades at $25.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 106.47, whereas DCPH's P/E ratio is -11.58. In terms of profitability, TXMD's ROE is -0.01%, compared to DCPH's ROE of -0.56%. Regarding short-term risk, TXMD is more volatile compared to DCPH. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check DCPH's competition here
Bausch Health Companies Inc. (NYSE: BHC)
TXMD vs BHC Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 24.2M. In comparison, BHC has a market cap of 2.2B. Regarding current trading prices, TXMD is priced at $2.09 on the NASDAQ, while BHC trades at $5.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 106.47, whereas BHC's P/E ratio is 1.47. In terms of profitability, TXMD's ROE is -0.01%, compared to BHC's ROE of +0.89%. Regarding short-term risk, TXMD is less volatile compared to BHC. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check BHC's competition here
Avadel Pharmaceuticals plc (NASDAQ: AVDL)
TXMD vs AVDL Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 24.2M. In comparison, AVDL has a market cap of 2.1B. Regarding current trading prices, TXMD is priced at $2.09 on the NASDAQ, while AVDL trades at $21.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 106.47, whereas AVDL's P/E ratio is -1082.00. In terms of profitability, TXMD's ROE is -0.01%, compared to AVDL's ROE of +0.05%. Regarding short-term risk, TXMD is more volatile compared to AVDL. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check AVDL's competition here
Trulieve Cannabis Corp. (NYSE: TRLV)
TXMD vs TRLV Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 24.2M. In comparison, TRLV has a market cap of 2.1B. Regarding current trading prices, TXMD is priced at $2.09 on the NASDAQ, while TRLV trades at $12.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 106.47, whereas TRLV's P/E ratio is -5.02. In terms of profitability, TXMD's ROE is -0.01%, compared to TRLV's ROE of -0.44%. Regarding short-term risk, TXMD is less volatile compared to TRLV. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check TRLV's competition here
Perrigo Company plc (NYSE: PRGO)
TXMD vs PRGO Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 24.2M. In comparison, PRGO has a market cap of 2.1B. Regarding current trading prices, TXMD is priced at $2.09 on the NASDAQ, while PRGO trades at $15.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 106.47, whereas PRGO's P/E ratio is 6.03. In terms of profitability, TXMD's ROE is -0.01%, compared to PRGO's ROE of -0.56%. Regarding short-term risk, TXMD is less volatile compared to PRGO. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check PRGO's competition here
Alvotech (NASDAQ: ALVO)
TXMD vs ALVO Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 24.2M. In comparison, ALVO has a market cap of 2.1B. Regarding current trading prices, TXMD is priced at $2.09 on the NASDAQ, while ALVO trades at $6.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 106.47, whereas ALVO's P/E ratio is -10.42. In terms of profitability, TXMD's ROE is -0.01%, compared to ALVO's ROE of +0.77%. Regarding short-term risk, TXMD is less volatile compared to ALVO. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check ALVO's competition here
Embecta Corp. (NASDAQ: EMBCV)
TXMD vs EMBCV Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 24.2M. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, TXMD is priced at $2.09 on the NASDAQ, while EMBCV trades at $33.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 106.47, whereas EMBCV's P/E ratio is N/A. In terms of profitability, TXMD's ROE is -0.01%, compared to EMBCV's ROE of -0.19%. Regarding short-term risk, TXMD is less volatile compared to EMBCV. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check EMBCV's competition here
Dynavax Technologies Corporation (NASDAQ: DVAX)
TXMD vs DVAX Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 24.2M. In comparison, DVAX has a market cap of 1.8B. Regarding current trading prices, TXMD is priced at $2.09 on the NASDAQ, while DVAX trades at $15.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 106.47, whereas DVAX's P/E ratio is -41.89. In terms of profitability, TXMD's ROE is -0.01%, compared to DVAX's ROE of -0.10%. Regarding short-term risk, TXMD is more volatile compared to DVAX. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check DVAX's competition here
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP)
TXMD vs ANIP Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 24.2M. In comparison, ANIP has a market cap of 1.7B. Regarding current trading prices, TXMD is priced at $2.09 on the NASDAQ, while ANIP trades at $74.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 106.47, whereas ANIP's P/E ratio is 9.10. In terms of profitability, TXMD's ROE is -0.01%, compared to ANIP's ROE of +0.19%. Regarding short-term risk, TXMD is more volatile compared to ANIP. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check ANIP's competition here
Eton Pharmaceuticals, Inc. (NASDAQ: ETON)
TXMD vs ETON Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 24.2M. In comparison, ETON has a market cap of 1.6B. Regarding current trading prices, TXMD is priced at $2.09 on the NASDAQ, while ETON trades at $59.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 106.47, whereas ETON's P/E ratio is 155.74. In terms of profitability, TXMD's ROE is -0.01%, compared to ETON's ROE of +0.40%. Regarding short-term risk, TXMD is less volatile compared to ETON. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check ETON's competition here
Taro Pharmaceutical Industries Ltd. (NYSE: TARO)
TXMD vs TARO Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 24.2M. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, TXMD is priced at $2.09 on the NASDAQ, while TARO trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 106.47, whereas TARO's P/E ratio is 30.05. In terms of profitability, TXMD's ROE is -0.01%, compared to TARO's ROE of +0.03%. Regarding short-term risk, TXMD is more volatile compared to TARO. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check TARO's competition here
Phibro Animal Health Corporation (NASDAQ: PAHC)
TXMD vs PAHC Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 24.2M. In comparison, PAHC has a market cap of 1.4B. Regarding current trading prices, TXMD is priced at $2.09 on the NASDAQ, while PAHC trades at $35.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 106.47, whereas PAHC's P/E ratio is 12.18. In terms of profitability, TXMD's ROE is -0.01%, compared to PAHC's ROE of +0.29%. Regarding short-term risk, TXMD is less volatile compared to PAHC. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check PAHC's competition here
Cronos Group Inc. (NASDAQ: CRON)
TXMD vs CRON Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 24.2M. In comparison, CRON has a market cap of 1.3B. Regarding current trading prices, TXMD is priced at $2.09 on the NASDAQ, while CRON trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 106.47, whereas CRON's P/E ratio is 17.46. In terms of profitability, TXMD's ROE is -0.01%, compared to CRON's ROE of +0.06%. Regarding short-term risk, TXMD is less volatile compared to CRON. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check CRON's competition here
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH)
TXMD vs AMPH Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 24.2M. In comparison, AMPH has a market cap of 1.2B. Regarding current trading prices, TXMD is priced at $2.09 on the NASDAQ, while AMPH trades at $27.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 106.47, whereas AMPH's P/E ratio is 9.35. In terms of profitability, TXMD's ROE is -0.01%, compared to AMPH's ROE of +0.10%. Regarding short-term risk, TXMD is less volatile compared to AMPH. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check AMPH's competition here
Harrow Health, Inc. (NASDAQ: HROW)
TXMD vs HROW Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 24.2M. In comparison, HROW has a market cap of 1.2B. Regarding current trading prices, TXMD is priced at $2.09 on the NASDAQ, while HROW trades at $31.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 106.47, whereas HROW's P/E ratio is -31.92. In terms of profitability, TXMD's ROE is -0.01%, compared to HROW's ROE of -1.04%. Regarding short-term risk, TXMD is less volatile compared to HROW. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check HROW's competition here
Pacira BioSciences, Inc. (NASDAQ: PCRX)
TXMD vs PCRX Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 24.2M. In comparison, PCRX has a market cap of 998.7M. Regarding current trading prices, TXMD is priced at $2.09 on the NASDAQ, while PCRX trades at $25.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 106.47, whereas PCRX's P/E ratio is 9.77. In terms of profitability, TXMD's ROE is -0.01%, compared to PCRX's ROE of +0.02%. Regarding short-term risk, TXMD is less volatile compared to PCRX. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check PCRX's competition here
PetIQ, Inc. (NASDAQ: PETQ)
TXMD vs PETQ Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 24.2M. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, TXMD is priced at $2.09 on the NASDAQ, while PETQ trades at $30.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 106.47, whereas PETQ's P/E ratio is 83.73. In terms of profitability, TXMD's ROE is -0.01%, compared to PETQ's ROE of +0.01%. Regarding short-term risk, TXMD is more volatile compared to PETQ. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check PETQ's competition here
Collegium Pharmaceutical, Inc. (NASDAQ: COLL)
TXMD vs COLL Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 24.2M. In comparison, COLL has a market cap of 734M. Regarding current trading prices, TXMD is priced at $2.09 on the NASDAQ, while COLL trades at $22.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 106.47, whereas COLL's P/E ratio is 2.84. In terms of profitability, TXMD's ROE is -0.01%, compared to COLL's ROE of +0.16%. Regarding short-term risk, TXMD is less volatile compared to COLL. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check COLL's competition here
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD)
TXMD vs IRWD Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 24.2M. In comparison, IRWD has a market cap of 678.2M. Regarding current trading prices, TXMD is priced at $2.09 on the NASDAQ, while IRWD trades at $4.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 106.47, whereas IRWD's P/E ratio is 5.28. In terms of profitability, TXMD's ROE is -0.01%, compared to IRWD's ROE of -0.57%. Regarding short-term risk, TXMD is less volatile compared to IRWD. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check IRWD's competition here
Aquestive Therapeutics, Inc. (NASDAQ: AQST)
TXMD vs AQST Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 24.2M. In comparison, AQST has a market cap of 596M. Regarding current trading prices, TXMD is priced at $2.09 on the NASDAQ, while AQST trades at $4.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 106.47, whereas AQST's P/E ratio is -7.31. In terms of profitability, TXMD's ROE is -0.01%, compared to AQST's ROE of +2.44%. Regarding short-term risk, TXMD is less volatile compared to AQST. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check AQST's competition here
BioDelivery Sciences International, Inc. (NASDAQ: BDSI)
TXMD vs BDSI Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 24.2M. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, TXMD is priced at $2.09 on the NASDAQ, while BDSI trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 106.47, whereas BDSI's P/E ratio is 6.82. In terms of profitability, TXMD's ROE is -0.01%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, TXMD is more volatile compared to BDSI. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check BDSI's competition here
Evotec SE (NASDAQ: EVO)
TXMD vs EVO Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 24.2M. In comparison, EVO has a market cap of 564.8M. Regarding current trading prices, TXMD is priced at $2.09 on the NASDAQ, while EVO trades at $1.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 106.47, whereas EVO's P/E ratio is -2.25. In terms of profitability, TXMD's ROE is -0.01%, compared to EVO's ROE of -0.27%. Regarding short-term risk, TXMD is more volatile compared to EVO. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check EVO's competition here
Glass House Brands Inc (NYSE: GLAS)
TXMD vs GLAS Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 24.2M. In comparison, GLAS has a market cap of 529.2M. Regarding current trading prices, TXMD is priced at $2.09 on the NASDAQ, while GLAS trades at $6.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 106.47, whereas GLAS's P/E ratio is -12.22. In terms of profitability, TXMD's ROE is -0.01%, compared to GLAS's ROE of -0.51%. Regarding short-term risk, TXMD is less volatile compared to GLAS. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check GLAS's competition here
Evolus, Inc. (NASDAQ: EOLS)
TXMD vs EOLS Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 24.2M. In comparison, EOLS has a market cap of 524.2M. Regarding current trading prices, TXMD is priced at $2.09 on the NASDAQ, while EOLS trades at $7.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 106.47, whereas EOLS's P/E ratio is -25.21. In terms of profitability, TXMD's ROE is -0.01%, compared to EOLS's ROE of +1.23%. Regarding short-term risk, TXMD is less volatile compared to EOLS. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check EOLS's competition here
Kamada Ltd. (NASDAQ: KMDA)
TXMD vs KMDA Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 24.2M. In comparison, KMDA has a market cap of 497.3M. Regarding current trading prices, TXMD is priced at $2.09 on the NASDAQ, while KMDA trades at $8.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 106.47, whereas KMDA's P/E ratio is 22.68. In terms of profitability, TXMD's ROE is -0.01%, compared to KMDA's ROE of +0.08%. Regarding short-term risk, TXMD is less volatile compared to KMDA. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check KMDA's competition here
Alpha Teknova, Inc. (NASDAQ: TKNO)
TXMD vs TKNO Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 24.2M. In comparison, TKNO has a market cap of 493.2M. Regarding current trading prices, TXMD is priced at $2.09 on the NASDAQ, while TKNO trades at $9.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 106.47, whereas TKNO's P/E ratio is -29.68. In terms of profitability, TXMD's ROE is -0.01%, compared to TKNO's ROE of -0.25%. Regarding short-term risk, TXMD is less volatile compared to TKNO. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check TKNO's competition here
Tilray Brands, Inc. (NASDAQ: TLRY)
TXMD vs TLRY Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 24.2M. In comparison, TLRY has a market cap of 449.6M. Regarding current trading prices, TXMD is priced at $2.09 on the NASDAQ, while TLRY trades at $4.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 106.47, whereas TLRY's P/E ratio is -3.71. In terms of profitability, TXMD's ROE is -0.01%, compared to TLRY's ROE of -0.08%. Regarding short-term risk, TXMD is less volatile compared to TLRY. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check TLRY's competition here
Canopy Growth Corporation (NASDAQ: CGC)
TXMD vs CGC Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 24.2M. In comparison, CGC has a market cap of 390.7M. Regarding current trading prices, TXMD is priced at $2.09 on the NASDAQ, while CGC trades at $0.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 106.47, whereas CGC's P/E ratio is -2.07. In terms of profitability, TXMD's ROE is -0.01%, compared to CGC's ROE of -0.33%. Regarding short-term risk, TXMD is more volatile compared to CGC. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check CGC's competition here
Emergent BioSolutions Inc. (NYSE: EBS)
TXMD vs EBS Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 24.2M. In comparison, EBS has a market cap of 354M. Regarding current trading prices, TXMD is priced at $2.09 on the NASDAQ, while EBS trades at $6.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 106.47, whereas EBS's P/E ratio is 4.76. In terms of profitability, TXMD's ROE is -0.01%, compared to EBS's ROE of -0.36%. Regarding short-term risk, TXMD is less volatile compared to EBS. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check EBS's competition here
Alimera Sciences, Inc. (NASDAQ: ALIM)
TXMD vs ALIM Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 24.2M. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, TXMD is priced at $2.09 on the NASDAQ, while ALIM trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 106.47, whereas ALIM's P/E ratio is 5.28. In terms of profitability, TXMD's ROE is -0.01%, compared to ALIM's ROE of -1.59%. Regarding short-term risk, TXMD is more volatile compared to ALIM. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check ALIM's competition here
Landec Corporation (NASDAQ: LNDC)
TXMD vs LNDC Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 24.2M. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, TXMD is priced at $2.09 on the NASDAQ, while LNDC trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 106.47, whereas LNDC's P/E ratio is -4.04. In terms of profitability, TXMD's ROE is -0.01%, compared to LNDC's ROE of +6.44%. Regarding short-term risk, TXMD is less volatile compared to LNDC. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check LNDC's competition here
Aurora Cannabis Inc. (NASDAQ: ACB)
TXMD vs ACB Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 24.2M. In comparison, ACB has a market cap of 253.3M. Regarding current trading prices, TXMD is priced at $2.09 on the NASDAQ, while ACB trades at $4.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 106.47, whereas ACB's P/E ratio is -2.95. In terms of profitability, TXMD's ROE is -0.01%, compared to ACB's ROE of -0.21%. Regarding short-term risk, TXMD is less volatile compared to ACB. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check ACB's competition here
SIGA Technologies, Inc. (NASDAQ: SIGA)
TXMD vs SIGA Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 24.2M. In comparison, SIGA has a market cap of 248.2M. Regarding current trading prices, TXMD is priced at $2.09 on the NASDAQ, while SIGA trades at $3.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 106.47, whereas SIGA's P/E ratio is 12.81. In terms of profitability, TXMD's ROE is -0.01%, compared to SIGA's ROE of -0.02%. Regarding short-term risk, TXMD is less volatile compared to SIGA. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check SIGA's competition here
Lifecore Biomedical, Inc. (NASDAQ: LFCR)
TXMD vs LFCR Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 24.2M. In comparison, LFCR has a market cap of 244.6M. Regarding current trading prices, TXMD is priced at $2.09 on the NASDAQ, while LFCR trades at $6.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 106.47, whereas LFCR's P/E ratio is -5.13. In terms of profitability, TXMD's ROE is -0.01%, compared to LFCR's ROE of -3.77%. Regarding short-term risk, TXMD is less volatile compared to LFCR. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check LFCR's competition here
Shineco, Inc. (NASDAQ: TYHT)
TXMD vs TYHT Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 24.2M. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, TXMD is priced at $2.09 on the NASDAQ, while TYHT trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 106.47, whereas TYHT's P/E ratio is -1.61. In terms of profitability, TXMD's ROE is -0.01%, compared to TYHT's ROE of -0.57%. Regarding short-term risk, TXMD is less volatile compared to TYHT. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check TYHT's competition here
Cardiol Therapeutics Inc. (NASDAQ: CRDL)
TXMD vs CRDL Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 24.2M. In comparison, CRDL has a market cap of 194.8M. Regarding current trading prices, TXMD is priced at $2.09 on the NASDAQ, while CRDL trades at $1.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 106.47, whereas CRDL's P/E ratio is -6.73. In terms of profitability, TXMD's ROE is -0.01%, compared to CRDL's ROE of -1.94%. Regarding short-term risk, TXMD is more volatile compared to CRDL. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check CRDL's competition here
Organogenesis Holdings Inc. (NASDAQ: ORGO)
TXMD vs ORGO Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 24.2M. In comparison, ORGO has a market cap of 177.6M. Regarding current trading prices, TXMD is priced at $2.09 on the NASDAQ, while ORGO trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 106.47, whereas ORGO's P/E ratio is 46.00. In terms of profitability, TXMD's ROE is -0.01%, compared to ORGO's ROE of -0.24%. Regarding short-term risk, TXMD is less volatile compared to ORGO. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check ORGO's competition here
Recro Pharma, Inc. (NASDAQ: REPH)
TXMD vs REPH Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 24.2M. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, TXMD is priced at $2.09 on the NASDAQ, while REPH trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 106.47, whereas REPH's P/E ratio is -8.04. In terms of profitability, TXMD's ROE is -0.01%, compared to REPH's ROE of -0.22%. Regarding short-term risk, TXMD is less volatile compared to REPH. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check REPH's competition here
Journey Medical Corporation (NASDAQ: DERM)
TXMD vs DERM Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 24.2M. In comparison, DERM has a market cap of 177M. Regarding current trading prices, TXMD is priced at $2.09 on the NASDAQ, while DERM trades at $6.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 106.47, whereas DERM's P/E ratio is -29.23. In terms of profitability, TXMD's ROE is -0.01%, compared to DERM's ROE of -0.20%. Regarding short-term risk, TXMD is less volatile compared to DERM. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check DERM's competition here
Theratechnologies Inc. (NASDAQ: THTX)
TXMD vs THTX Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 24.2M. In comparison, THTX has a market cap of 155.9M. Regarding current trading prices, TXMD is priced at $2.09 on the NASDAQ, while THTX trades at $3.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 106.47, whereas THTX's P/E ratio is -28.83. In terms of profitability, TXMD's ROE is -0.01%, compared to THTX's ROE of +0.36%. Regarding short-term risk, TXMD is more volatile compared to THTX. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check THTX's competition here
Organigram Global Inc. (NASDAQ: OGI)
TXMD vs OGI Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 24.2M. In comparison, OGI has a market cap of 152.7M. Regarding current trading prices, TXMD is priced at $2.09 on the NASDAQ, while OGI trades at $1.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 106.47, whereas OGI's P/E ratio is 2.44. In terms of profitability, TXMD's ROE is -0.01%, compared to OGI's ROE of +0.21%. Regarding short-term risk, TXMD is less volatile compared to OGI. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check OGI's competition here
Assertio Holdings, Inc. (NASDAQ: ASRT)
TXMD vs ASRT Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 24.2M. In comparison, ASRT has a market cap of 151.9M. Regarding current trading prices, TXMD is priced at $2.09 on the NASDAQ, while ASRT trades at $23.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 106.47, whereas ASRT's P/E ratio is -7.10. In terms of profitability, TXMD's ROE is -0.01%, compared to ASRT's ROE of -0.39%. Regarding short-term risk, TXMD is more volatile compared to ASRT. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check ASRT's competition here
Societal CDMO, Inc. (NASDAQ: SCTL)
TXMD vs SCTL Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 24.2M. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, TXMD is priced at $2.09 on the NASDAQ, while SCTL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 106.47, whereas SCTL's P/E ratio is -7.86. In terms of profitability, TXMD's ROE is -0.01%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, TXMD is more volatile compared to SCTL. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check SCTL's competition here
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX)
TXMD vs CPIX Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 24.2M. In comparison, CPIX has a market cap of 115.7M. Regarding current trading prices, TXMD is priced at $2.09 on the NASDAQ, while CPIX trades at $7.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 106.47, whereas CPIX's P/E ratio is -19.30. In terms of profitability, TXMD's ROE is -0.01%, compared to CPIX's ROE of -0.47%. Regarding short-term risk, TXMD is less volatile compared to CPIX. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check CPIX's competition here
Procaps Group S.A. (NASDAQ: PROC)
TXMD vs PROC Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 24.2M. In comparison, PROC has a market cap of 102.1M. Regarding current trading prices, TXMD is priced at $2.09 on the NASDAQ, while PROC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 106.47, whereas PROC's P/E ratio is 1.53. In terms of profitability, TXMD's ROE is -0.01%, compared to PROC's ROE of -2.22%. Regarding short-term risk, TXMD is more volatile compared to PROC. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check PROC's competition here
OptiNose, Inc. (NASDAQ: OPTN)
TXMD vs OPTN Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 24.2M. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, TXMD is priced at $2.09 on the NASDAQ, while OPTN trades at $9.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 106.47, whereas OPTN's P/E ratio is -4.42. In terms of profitability, TXMD's ROE is -0.01%, compared to OPTN's ROE of +0.34%. Regarding short-term risk, TXMD is more volatile compared to OPTN. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check OPTN's competition here
Zomedica Corp. (AMEX: ZOM)
TXMD vs ZOM Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 24.2M. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, TXMD is priced at $2.09 on the NASDAQ, while ZOM trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 106.47, whereas ZOM's P/E ratio is -1.62. In terms of profitability, TXMD's ROE is -0.01%, compared to ZOM's ROE of -0.17%. Regarding short-term risk, TXMD is less volatile compared to ZOM. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check ZOM's competition here
Upexi, Inc. (NASDAQ: GRVI)
TXMD vs GRVI Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 24.2M. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, TXMD is priced at $2.09 on the NASDAQ, while GRVI trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 106.47, whereas GRVI's P/E ratio is 26.05. In terms of profitability, TXMD's ROE is -0.01%, compared to GRVI's ROE of -4.51%. Regarding short-term risk, TXMD is less volatile compared to GRVI. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check GRVI's competition here
BGM Group Ltd. (NASDAQ: BGM)
TXMD vs BGM Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 24.2M. In comparison, BGM has a market cap of 88.8M. Regarding current trading prices, TXMD is priced at $2.09 on the NASDAQ, while BGM trades at $0.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 106.47, whereas BGM's P/E ratio is -1.46. In terms of profitability, TXMD's ROE is -0.01%, compared to BGM's ROE of -0.05%. Regarding short-term risk, TXMD is less volatile compared to BGM. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check BGM's competition here
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE)
TXMD vs ZYNE Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 24.2M. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, TXMD is priced at $2.09 on the NASDAQ, while ZYNE trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 106.47, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, TXMD's ROE is -0.01%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, TXMD is less volatile compared to ZYNE. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check ZYNE's competition here
Silver Spike Investment Corp. (NASDAQ: SSIC)
TXMD vs SSIC Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 24.2M. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, TXMD is priced at $2.09 on the NASDAQ, while SSIC trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 106.47, whereas SSIC's P/E ratio is 11.93. In terms of profitability, TXMD's ROE is -0.01%, compared to SSIC's ROE of +0.00%. Regarding short-term risk, TXMD is more volatile compared to SSIC. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check SSIC's competition here
Talphera, Inc. (NASDAQ: TLPH)
TXMD vs TLPH Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 24.2M. In comparison, TLPH has a market cap of 61.8M. Regarding current trading prices, TXMD is priced at $2.09 on the NASDAQ, while TLPH trades at $1.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 106.47, whereas TLPH's P/E ratio is -3.84. In terms of profitability, TXMD's ROE is -0.01%, compared to TLPH's ROE of -0.87%. Regarding short-term risk, TXMD is less volatile compared to TLPH. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check TLPH's competition here
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT)
TXMD vs ZYBT Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 24.2M. In comparison, ZYBT has a market cap of 61.6M. Regarding current trading prices, TXMD is priced at $2.09 on the NASDAQ, while ZYBT trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 106.47, whereas ZYBT's P/E ratio is -6.32. In terms of profitability, TXMD's ROE is -0.01%, compared to ZYBT's ROE of -0.27%. Regarding short-term risk, TXMD is less volatile compared to ZYBT. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check ZYBT's competition here
The Valens Company Inc. (NASDAQ: VLNS)
TXMD vs VLNS Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 24.2M. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, TXMD is priced at $2.09 on the NASDAQ, while VLNS trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 106.47, whereas VLNS's P/E ratio is -1.03. In terms of profitability, TXMD's ROE is -0.01%, compared to VLNS's ROE of N/A. Regarding short-term risk, TXMD is less volatile compared to VLNS. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check VLNS's competition here
InterCure Ltd. (NASDAQ: INCR)
TXMD vs INCR Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 24.2M. In comparison, INCR has a market cap of 60.7M. Regarding current trading prices, TXMD is priced at $2.09 on the NASDAQ, while INCR trades at $5.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 106.47, whereas INCR's P/E ratio is -4.92. In terms of profitability, TXMD's ROE is -0.01%, compared to INCR's ROE of -0.09%. Regarding short-term risk, TXMD is more volatile compared to INCR. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check INCR's competition here
DURECT Corporation (NASDAQ: DRRX)
TXMD vs DRRX Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 24.2M. In comparison, DRRX has a market cap of 59.3M. Regarding current trading prices, TXMD is priced at $2.09 on the NASDAQ, while DRRX trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 106.47, whereas DRRX's P/E ratio is -4.44. In terms of profitability, TXMD's ROE is -0.01%, compared to DRRX's ROE of -1.40%. Regarding short-term risk, TXMD is more volatile compared to DRRX. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check DRRX's competition here
Jupiter Wellness, Inc. (NASDAQ: JUPW)
TXMD vs JUPW Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 24.2M. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, TXMD is priced at $2.09 on the NASDAQ, while JUPW trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 106.47, whereas JUPW's P/E ratio is -2.41. In terms of profitability, TXMD's ROE is -0.01%, compared to JUPW's ROE of -3.04%. Regarding short-term risk, TXMD is less volatile compared to JUPW. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check JUPW's competition here
Qilian International Holding Group Limited (NASDAQ: QLI)
TXMD vs QLI Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 24.2M. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, TXMD is priced at $2.09 on the NASDAQ, while QLI trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 106.47, whereas QLI's P/E ratio is -4.92. In terms of profitability, TXMD's ROE is -0.01%, compared to QLI's ROE of -0.16%. Regarding short-term risk, TXMD is more volatile compared to QLI. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check QLI's competition here
Rockwell Medical, Inc. (NASDAQ: RMTI)
TXMD vs RMTI Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 24.2M. In comparison, RMTI has a market cap of 34.1M. Regarding current trading prices, TXMD is priced at $2.09 on the NASDAQ, while RMTI trades at $8.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 106.47, whereas RMTI's P/E ratio is -6.44. In terms of profitability, TXMD's ROE is -0.01%, compared to RMTI's ROE of -0.14%. Regarding short-term risk, TXMD is less volatile compared to RMTI. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check RMTI's competition here
HEXO Corp. (NASDAQ: HEXO)
TXMD vs HEXO Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 24.2M. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, TXMD is priced at $2.09 on the NASDAQ, while HEXO trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 106.47, whereas HEXO's P/E ratio is -0.26. In terms of profitability, TXMD's ROE is -0.01%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, TXMD is less volatile compared to HEXO. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check HEXO's competition here
China Pharma Holdings, Inc. (AMEX: CPHI)
TXMD vs CPHI Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 24.2M. In comparison, CPHI has a market cap of 29.5M. Regarding current trading prices, TXMD is priced at $2.09 on the NASDAQ, while CPHI trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 106.47, whereas CPHI's P/E ratio is -1.69. In terms of profitability, TXMD's ROE is -0.01%, compared to CPHI's ROE of -0.17%. Regarding short-term risk, TXMD is less volatile compared to CPHI. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check CPHI's competition here
Cyclo Therapeutics, Inc. (NASDAQ: CYTH)
TXMD vs CYTH Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 24.2M. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, TXMD is priced at $2.09 on the NASDAQ, while CYTH trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 106.47, whereas CYTH's P/E ratio is -0.80. In terms of profitability, TXMD's ROE is -0.01%, compared to CYTH's ROE of -7.30%. Regarding short-term risk, TXMD is more volatile compared to CYTH. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check CYTH's competition here
Aytu BioPharma, Inc. (NASDAQ: AYTU)
TXMD vs AYTU Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 24.2M. In comparison, AYTU has a market cap of 23.3M. Regarding current trading prices, TXMD is priced at $2.09 on the NASDAQ, while AYTU trades at $2.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 106.47, whereas AYTU's P/E ratio is -0.47. In terms of profitability, TXMD's ROE is -0.01%, compared to AYTU's ROE of -0.53%. Regarding short-term risk, TXMD is less volatile compared to AYTU. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check AYTU's competition here
Evoke Pharma, Inc. (NASDAQ: EVOK)
TXMD vs EVOK Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 24.2M. In comparison, EVOK has a market cap of 18.9M. Regarding current trading prices, TXMD is priced at $2.09 on the NASDAQ, while EVOK trades at $11.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 106.47, whereas EVOK's P/E ratio is -7.97. In terms of profitability, TXMD's ROE is -0.01%, compared to EVOK's ROE of -0.89%. Regarding short-term risk, TXMD is more volatile compared to EVOK. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check EVOK's competition here
Optimi Health Corp. (NASDAQ: OPTH)
TXMD vs OPTH Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 24.2M. In comparison, OPTH has a market cap of 15.6M. Regarding current trading prices, TXMD is priced at $2.09 on the NASDAQ, while OPTH trades at $4.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 106.47, whereas OPTH's P/E ratio is -3.37. In terms of profitability, TXMD's ROE is -0.01%, compared to OPTH's ROE of -0.90%. Regarding short-term risk, TXMD is less volatile compared to OPTH. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check OPTH's competition here
AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX)
TXMD vs ACRX Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 24.2M. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, TXMD is priced at $2.09 on the NASDAQ, while ACRX trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 106.47, whereas ACRX's P/E ratio is -0.31. In terms of profitability, TXMD's ROE is -0.01%, compared to ACRX's ROE of -0.87%. Regarding short-term risk, TXMD is less volatile compared to ACRX. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check ACRX's competition here
Caring Brands, Inc. (NASDAQ: CABR)
TXMD vs CABR Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 24.2M. In comparison, CABR has a market cap of 11.3M. Regarding current trading prices, TXMD is priced at $2.09 on the NASDAQ, while CABR trades at $1.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 106.47, whereas CABR's P/E ratio is -1.59. In terms of profitability, TXMD's ROE is -0.01%, compared to CABR's ROE of -3.86%. Regarding short-term risk, TXMD is less volatile compared to CABR. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check CABR's competition here
Agile Therapeutics, Inc. (NASDAQ: AGRX)
TXMD vs AGRX Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 24.2M. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, TXMD is priced at $2.09 on the NASDAQ, while AGRX trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 106.47, whereas AGRX's P/E ratio is -0.89. In terms of profitability, TXMD's ROE is -0.01%, compared to AGRX's ROE of +1.32%. Regarding short-term risk, TXMD is less volatile compared to AGRX. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check AGRX's competition here
Neoleukin Therapeutics, Inc. (NASDAQ: NLTX)
TXMD vs NLTX Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 24.2M. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, TXMD is priced at $2.09 on the NASDAQ, while NLTX trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 106.47, whereas NLTX's P/E ratio is -0.28. In terms of profitability, TXMD's ROE is -0.01%, compared to NLTX's ROE of -0.45%. Regarding short-term risk, TXMD is less volatile compared to NLTX. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check NLTX's competition here
Lannett Company, Inc. (NYSE: LCI)
TXMD vs LCI Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 24.2M. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, TXMD is priced at $2.09 on the NASDAQ, while LCI trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 106.47, whereas LCI's P/E ratio is -0.04. In terms of profitability, TXMD's ROE is -0.01%, compared to LCI's ROE of +1.66%. Regarding short-term risk, TXMD is less volatile compared to LCI. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check LCI's competition here
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP)
TXMD vs ADMP Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 24.2M. In comparison, ADMP has a market cap of 7.3M. Regarding current trading prices, TXMD is priced at $2.09 on the NASDAQ, while ADMP trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 106.47, whereas ADMP's P/E ratio is -0.08. In terms of profitability, TXMD's ROE is -0.01%, compared to ADMP's ROE of -2.09%. Regarding short-term risk, TXMD is less volatile compared to ADMP. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check ADMP's competition here
Gelteq Limited Ordinary Shares (NASDAQ: GELS)
TXMD vs GELS Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 24.2M. In comparison, GELS has a market cap of 5M. Regarding current trading prices, TXMD is priced at $2.09 on the NASDAQ, while GELS trades at $0.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 106.47, whereas GELS's P/E ratio is -1.09. In terms of profitability, TXMD's ROE is -0.01%, compared to GELS's ROE of -0.25%. Regarding short-term risk, TXMD is less volatile compared to GELS. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check GELS's competition here
cbdMD, Inc. (AMEX: YCBD)
TXMD vs YCBD Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 24.2M. In comparison, YCBD has a market cap of 4.9M. Regarding current trading prices, TXMD is priced at $2.09 on the NASDAQ, while YCBD trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 106.47, whereas YCBD's P/E ratio is -1.14. In terms of profitability, TXMD's ROE is -0.01%, compared to YCBD's ROE of -0.34%. Regarding short-term risk, TXMD is less volatile compared to YCBD. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check YCBD's competition here
Mallinckrodt plc (AMEX: MNK)
TXMD vs MNK Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 24.2M. In comparison, MNK has a market cap of 4.5M. Regarding current trading prices, TXMD is priced at $2.09 on the NASDAQ, while MNK trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 106.47, whereas MNK's P/E ratio is -0.44. In terms of profitability, TXMD's ROE is -0.01%, compared to MNK's ROE of -0.36%. Regarding short-term risk, TXMD is less volatile compared to MNK. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check MNK's competition here
Flora Growth Corp. (NASDAQ: FLGC)
TXMD vs FLGC Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 24.2M. In comparison, FLGC has a market cap of 4.2M. Regarding current trading prices, TXMD is priced at $2.09 on the NASDAQ, while FLGC trades at $7.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 106.47, whereas FLGC's P/E ratio is -0.19. In terms of profitability, TXMD's ROE is -0.01%, compared to FLGC's ROE of -3.03%. Regarding short-term risk, TXMD is less volatile compared to FLGC. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check FLGC's competition here
Universe Pharmaceuticals Inc. (NASDAQ: UPC)
TXMD vs UPC Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 24.2M. In comparison, UPC has a market cap of 3.1M. Regarding current trading prices, TXMD is priced at $2.09 on the NASDAQ, while UPC trades at $4.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 106.47, whereas UPC's P/E ratio is -0.61. In terms of profitability, TXMD's ROE is -0.01%, compared to UPC's ROE of -0.03%. Regarding short-term risk, TXMD is less volatile compared to UPC. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check UPC's competition here
PLx Pharma Inc. (NASDAQ: PLXP)
TXMD vs PLXP Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 24.2M. In comparison, PLXP has a market cap of 2.5M. Regarding current trading prices, TXMD is priced at $2.09 on the NASDAQ, while PLXP trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 106.47, whereas PLXP's P/E ratio is -0.22. In terms of profitability, TXMD's ROE is -0.01%, compared to PLXP's ROE of -1.66%. Regarding short-term risk, TXMD is less volatile compared to PLXP. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check PLXP's competition here
InMed Pharmaceuticals Inc. (NASDAQ: INM)
TXMD vs INM Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 24.2M. In comparison, INM has a market cap of 2.5M. Regarding current trading prices, TXMD is priced at $2.09 on the NASDAQ, while INM trades at $1.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 106.47, whereas INM's P/E ratio is -0.25. In terms of profitability, TXMD's ROE is -0.01%, compared to INM's ROE of -1.35%. Regarding short-term risk, TXMD is more volatile compared to INM. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check INM's competition here
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH)
TXMD vs SHPH Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 24.2M. In comparison, SHPH has a market cap of 2.4M. Regarding current trading prices, TXMD is priced at $2.09 on the NASDAQ, while SHPH trades at $4.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 106.47, whereas SHPH's P/E ratio is -0.19. In terms of profitability, TXMD's ROE is -0.01%, compared to SHPH's ROE of -1.57%. Regarding short-term risk, TXMD is less volatile compared to SHPH. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check SHPH's competition here
Athenex, Inc. (NASDAQ: ATNX)
TXMD vs ATNX Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 24.2M. In comparison, ATNX has a market cap of 2.3M. Regarding current trading prices, TXMD is priced at $2.09 on the NASDAQ, while ATNX trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 106.47, whereas ATNX's P/E ratio is -0.02. In terms of profitability, TXMD's ROE is -0.01%, compared to ATNX's ROE of +0.22%. Regarding short-term risk, TXMD is more volatile compared to ATNX. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check ATNX's competition here
Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA)
TXMD vs SNOA Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 24.2M. In comparison, SNOA has a market cap of 2.1M. Regarding current trading prices, TXMD is priced at $2.09 on the NASDAQ, while SNOA trades at $1.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 106.47, whereas SNOA's P/E ratio is -1.14. In terms of profitability, TXMD's ROE is -0.01%, compared to SNOA's ROE of -0.54%. Regarding short-term risk, TXMD is less volatile compared to SNOA. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check SNOA's competition here
Procaps Group, S.A. (NASDAQ: PROCW)
TXMD vs PROCW Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 24.2M. In comparison, PROCW has a market cap of 2M. Regarding current trading prices, TXMD is priced at $2.09 on the NASDAQ, while PROCW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 106.47, whereas PROCW's P/E ratio is N/A. In terms of profitability, TXMD's ROE is -0.01%, compared to PROCW's ROE of -2.22%. Regarding short-term risk, TXMD is more volatile compared to PROCW. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check PROCW's competition here